Gene Expression Profiling in Normal Tissue and Tumor Tissue From Patients With Colon Cancer That Has Spread to the Liver, Lungs, or Peritoneum
|ClinicalTrials.gov Identifier: NCT00896753|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : May 30, 2017
RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer may help doctors identify biomarkers related to cancer.
PURPOSE: This laboratory study is using gene expression profiling to evaluate normal tissue and tumor tissue from patients with colon cancer that has spread to the liver, lungs, or peritoneum.
|Condition or disease|
|Colorectal Cancer Metastatic Cancer|
- Evaluate gene expression profiles in normal and tumor tissue from patients with colon cancer metastatic to the liver, lungs, or peritoneum.
- Establish cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum.
- Determine the specific gene expression changes that result in the manifestation of the drug-resistant phenotype for each metastatic site.
OUTLINE: This is a pilot study.
Tumor and normal tissue collected during surgery are analyzed for gene expression profiling by cDNA microarray. Tissue is also analyzed for thymidylate synthase (TS) gene expression by quantitative PCR and for protein expression by western blot. Gene expression patterns are correlated with TS levels.
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Official Title:||Gene Expression Profiling of Metastatic Colon Cancer (CCCWFU 89B03)|
|Study Start Date :||September 2003|
|Primary Completion Date :||September 2006|
|Study Completion Date :||May 2008|
|patients with metastatic colon cancer|
- Gene expression changes that occur at each metastatic site (i.e., liver, lungs, and peritoneum) [ Time Frame: day 1 ]
- Development of cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum [ Time Frame: day 1 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00896753
|Study Chair:||Perry Shen, MD||Wake Forest University Health Sciences|